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Abstract
The high-risk HPV E6 and E7 proteins cooperate to immortalize primary human cervical cells and the E7 protein can
independently transform fibroblasts in vitro, primarily due to its ability to associate with and degrade the retinoblastoma
tumor suppressor protein, pRb. The binding of E7 to pRb is mediated by a conserved Leu-X-Cys-X-Glu (LXCXE) motif in the
conserved region 2 (CR2) of E7 and this domain is both necessary and sufficient for E7/pRb association. In the current study,
we report that the E7 protein of the malignancy-associated canine papillomavirus type 2 encodes an E7 protein that has
serine substituted for cysteine in the LXCXE motif. In HPV, this substitution in E7 abrogates pRb binding and degradation.
However, despite variation at this critical site, the canine papillomavirus E7 protein still bound and degraded pRb. Even
complete deletion of the LXSXE domain of canine E7 failed to interfere with binding to pRb in vitro and in vivo. Rather, the
dominant binding site for pRb mapped to the C-terminal domain of canine E7. Finally, while the CR1 and CR2 domains of
HPV E7 are sufficient for degradation of pRb, the C-terminal region of canine E7 was also required for pRb degradation.
Screening of HPV genome sequences revealed that the LXSXE motif of the canine E7 protein was also present in the gamma
HPVs and we demonstrate that the gamma HPV-4 E7 protein also binds pRb in a similar way. It appears, therefore, that the
type 2 canine PV and gamma-type HPVs not only share similar properties with respect to tissue specificity and association
with immunosuppression, but also the mechanism by which their E7 proteins interact with pRb.
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Introduction
Human papillomaviruses (HPVs) mediate the initiation and
maintenance of cervical cancer [1,2]. Based upon DNA sequence
homology, there are more than 150 different HPV genotypes, 40 of
which infect anogenital and oral mucosa [3]. In addition to
genotyping, HPVs can also be classified as low-risk and high-risk
based on the clinical prognosis of their associated lesions. Low-risk
HPVs cause benign epithelial hyperplasias while high-risk HPVs
cause lesions that can progress to malignancy. Integration of the
HPV genome into a host cell chromosome is a frequent event
during malignant progression and it may play a significant role in
dysregulated expression of the HPV E6 and E7 proteins [4]. The
high-risk HPV E6 binds to several cell targets, including p53, Myc,
E6AP, PDZ proteins and other cellular proteins to alter apoptotic/
growth regulatory pathways and induce cellular telomerase activity
[5]. The E7 protein binds and sequesters pRb and directs its
ubiquitin-mediated proteolysis [6], thereby altering E2F-regulated
genes and allowing cells to enter the S phase of the cell cycle.
The E7 oncoprotein is approximately 100 amino acids in length
and contains two highly conserved regions (CRs), the amino-
terminal CR1 and CR2 domains [7]. The E7 CR1 and CR2
domains share strikingly high homology with the CR1 and CR2
regions of adenovirus (Ad) E1A and related sequences in simian
vacuolating virus 40 (SV40) large tumor antigen (T Ag) [4,8]. For
each of these viruses, the CRs contribute significantly to cell
transformation [9,10,11,12]. A conserved Leu-X-Cys-X-Glu
(LXCXE) motif in the CR2 domain of HPV E7, as well the ones
in Adenovirus E1A and SV40 LT, are necessary and sufficient for
association with pRb [13]. The crystal structure of pRb bound to an
E7 peptide was resolved, and revealed that LXCXE of HPV E7
binds entirely through the B domain of pRb [14]. For high risk
HPV, the LXCXE motif is also required for pRb degrada-
tion[15,16]. The carboxyl-terminal domainof E7 consists of a metal
binding domain composed of two CXXC motifs separated from
each other by 29 amino acids [14]. This zinc-binding region is
important for E7 dimerization and intracellular stabilization
[10,17]. The carboxyl-terminal domain also contributes to E7
association with chromatin-modifying enzymes, particularly histone
deacetylases and histone acetyl transferases [18]. Although the
carboxyl-terminus of high-risk HPV E7 does not appear to have a
direct role in the binding and degradation of pRb [15,19], it has
been proposed to be important for releasing E2F from pRb [20,21].
Papillomavirus can be isolated from a wide range of vertebrates,
ranging from birds to manatees [22,23] and infection by these
viruses is, in general, species-specific. The canine papillomavirus
model has been used successfully for vaccine [24,25] and
therapeutics studies [26]. Recently, our lab isolated and sequenced
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which we showed to be an epidermotropic virus that occurred
frequently in immunosuppressed animals and induced tumors that
progressed to aggressive cancers [27,28]. The E7 gene of CPV-2
appeared unique in that it lacked the conserved LXCXE motif. In
this study we show that this variant E7 protein is still able to bind
and degrade pRb and that the primary domain for binding pRb is
in its carboxyl-terminus. Interestingly, upon searching the HPV
genome database, we observed that the gamma HPVs also
contained the variant LXSXE E7 domain and, similar to the
canine E7 protein, could still bind and degrade pRb. In addition to
this similarity, we also noted that both the type 2 canine PV and
gamma HPVs both exhibited a tropism for skin and for
immunocompromised hosts.
Materials and Methods
Plasmids
Wild-typeCPV-2E6andE7weregeneratedbyPCRusingCPV-
2 genome as template [27] and subcloned into retrovirus vector
pLXSN (Clontech) at the sites EcoR I and BamH I. The CPV-2 E7
mutants CPV-2 E7 DLXSXE, S26C, and S26G were generated by
using the QuikChange Site-Directed Mutagenesis kit (Stratagene),
and CR1, CR2, CR1CR2 and CT were generated by PCR using
pLXSN.CPV-2E7 as template. All the wild type E7 and mutants
were cloned into the sites EcoR I and Not I of the pGEX4T-2 (GE
Healthcare) for GST fusion protein expression. CPV-2 E7 and
mutants with a hemagglutinin (HA) epitope tag at their amino
terminal or carboxyl terminal were generated by PCR. PCR
products were then subcloned into the mammalian expression
vector pJS55 [29] at the sites EcoR I and BamH I. All plasmids were
sequenced to confirm the presence of corresponding mutations. All
primer sequences used in subcloning and site-directed mutagenesis
pleaseseeSupporting InformationS1.Allthe wild type and mutants
of HPV-4 E7 DNA (GenBank NC_001457.1) were synthesized
(Celtek Bioscience), and cloned into pGEX4T-2 (GE Healthcare)
for GST fusion protein expression.
Cell lines and culture
U2OS cells, Hela cells and SD3443 cells were maintained in
Dulbecco’s Modified Eagle’s Medium (DMEM) (Invitrogen)
supplemented with 10% Fetal Bovine Serum (FBS). Primary
human keratinocytes were derived from neonatal foreskins as
described previously [30] and were grown in Keratinocyte-SFM
medium (Invitrogen).
Transfection and retrovirus Infection
U2OS cells were co-transfected with RcCMV-Rb and pJs55,
pJS55-HA.HPV16 E7, pJS55-HA.CPV-2 E7DLXSXE, pJS55-
HA.CPV-2 E7CR1CR2, pJS55-HA.CPV-2 E7C-RT or pJS55-
HA.CPV-2 E7 using Lipofectamine 2000 (Invitrogen) as specified
by the manufacturer. Hela cells were transfected with pJs55,
pJS55-HA.HPV16 E7 or pJS55-HA.CPV-2 E7 using Lipofecta-
mine 2000 (Invitrogen) as specified by the manufacturer. Cell were
harvested and lysed by RIPA buffer (25 mM TrisNHCl pH 7.6,
150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS)
24 hours post transfection.
To prepare retrovirus stocks, SD3443 cells were transfected
with E7 retrovirus constructs using Fugen (Roche applied science,
US.) as specified by the manufacturer. Culture supernatants
containing retrovirus were collected 48 h post-transfection. Viral
titers of the supernatants were determined using 3T3 cells. The
primary HFK cells (passage 0) were infected at a multiplicity of 10
PFU/cell with retrovirus expressing wild type E6, E7 or E7
mutants. Retrovirus-infected cells were selected in G418 (50 ng/
ml) for 2 days.
GST fusion protein expression and purification
GST and GSTE7 fusion proteins were expressed in BL21pLysS
cells (Invitrogen). The cells were induced with 100 mM isopropyl-
b-D-thiogalactopyranoside (IPTG) 6 hours at 25uC once the
optical density at 600 nm reached 0.8–1.0. Recombinant CPV-2
E7 and mutants were purified from the supernatant of disrupted
cells by glutathione-Sepharose chromatography as previously
described [24].
Preparation of cell extracts and Western blot analysis
Proteins were extracted from cells and measured concentration
as previously described[31]. Proteins were separated on a 4 to 20%
Tris-glycine gradient gel (Novex) and then were electrophoretically
transferred to an Immobilon-P polyvinylidane difluorid (PVDF)
membrane (Millipore). The primary antibody was used at a
dilution of 1:1,000 or 1:3,000. The secondary antibodies, alkaline
phosphatase-conjugated goat anti-mouse IgG and anti-rabbit IgG
(Tropix) antibodies, were used at a dilution of 1:2,000. Western
blots were visualized by using SuperSignal West Pico Chemilu-
minescent Substrate (Thermo Scientific). The following commer-
cial antibodies were used: for pRb (1:1000 dilution), Rb (4H1)
Mouse mAb (Cell Signaling technology); for glutathione S-
transferase (1:3000 dilution), catalog no. 3818-1 (Clontech); for
HA (1:1000 dilution), HA.11 clone 16B12 (Covance).
Analysis of protein interactions
For GST pull-down assays, Jurkat cell or CPEK cell nuclear
extract (50 mg) was incubated with 5 mg of GST or GST fusion
protein in binding buffer [20 mM Hepes/150 mM KCl/4 mM
MgCl2/1 mM EDTA/0.02% Nonidet P-40/10% glycerol/
0.035% 2-mercaptoethanol/1% (vol/vol) Sigma protease inhibitor
mixture] and rocked for 1 h at 4uC. Glutathione-Sepharose beads
(Amersham Pharmacia Biosciences) were added to each reaction
and rocked for another 1 h at 4uC. The beads were then washed
with 1 ml of washing buffer (125 mM Tris, 150 mM NaCl,
pH 8.0) four times and boiled with 26SDS sample buffer, and the
proteins were separated by SDS/PAGE. Western blots were used
to measure the level of pRb and GSTE7 proteins. The bands of
pRb and GSTE7 proteins were quantified by densitometry using
Quantity One (BioRad). The relative binding activities were
calculated using pRb bound by wild type CPV-2 E7 GST fusion
protein as 100%, and normalized with GSTE7 bands.
Author Summary
Human papillomaviruses (HPVs) are estimated to cause the
most common sexually transmitted infection in the world,
and these infections are recognized as the major cause of
cervical cancer. One of the papillomavirus oncoproteins,
E7, plays a major role in both the viral life cycle and
progression to cancer. In cells E7 associates and inactivates
pRb, a tumor suppressor protein. For the vast majority of
papillomaviruses, E7 binds to pRb using a small amino acid
sequence, LXCXE. However, we have now identified a
papillomavirus E7 protein that lacks the LXCXE domain yet
still binds and degrades pRb. This E7 protein, derived from
a carcinogenic canine virus, uses its C-terminal domain to
bind pRb. In addition, we discovered that a family of
papillomaviruses, the gamma type HPVs, also lacks the
LXCXE domain and binds pRb using a similar mechanism.
New Mechanism for E7 Association with pRb
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CPV-2 E7 proteins were immunoprecipitated with a polyclonal
anti-pRb antibody (Santa cruz). C-terminal HA-tagged CPV-2 or
HPV16 E7 proteins were immunoprecipitated with a polyclonal
anti-HA antibody (Santa Cruz). Bead washing buffer was 25 mM
TrisNHCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium
deoxycholate, 0.1% SDS, 1% Sigma protease inhibitor mixture.
The pulled down complexes were resolved on a 4 to 20% gradient
gel and then analyzed by Western blotting using either anti-pRb
antibody, anti-HA antibody or anti-cullin2 antibody (Invitrogen).
Reverse transcription PCR
Cells in a 3.5 cm diameter dish were lysed with 1 ml TRIZOL
(Invitrogen). Total RNA was isolated according to manufacturer’s
protocol. Reverse transcription PCR was performed using ONE
STEP RT-PCR KIT (QIAGEN) as specified by the manufacturer.
All primer sequences and condition please see Supporting
Information S1.
Protein sequence analysis
Multiple sequence alignments of E7 were prepared using Clustal
W. The phyllogenetic analysis was conducted using the Mega
version 4.0 [32].
Results
Despite lacking the conserved LXCXE motif, CPV-2 E7 can
still degrade pRb in cells
Several studies have demonstrated that the conserved LXCXE
motif in the HPV E7 CR2 domain is necessary and sufficient for
binding pRb [4]). Studies have also revealed that the substitution of C
or E or complete deletion mutation of the LXCXE motif destroys
pRb binding. Without binding to the pRb, E7 is unable to degrade
pRb [4]. Our laboratory recently isolated CPV-2 from footpad and
interdigital papillomas of immunosuppressed dogs. Sequencing
revealed that the CPV-2 E7 protein contained the typical two C-
X-X-C motifs within its carboxyl terminal half but lacked the
conserved pRb binding site (LXCXE) which is present in COPV
(CPV-1) E7 and most HPVs (Figure 1A). CPV-2 E7 has a serine
(amino acid 26) in the position of cysteine in the LXCXE motif. In
order to test whether CPV-2 E7 could degrade pRb, canine E7 was
transduced into human keratinocytes (HFKs), canine kidney cells
(MDCKs) or canine keratinocytes (CPEKs) by using retrovirus
infection. Cell lysates were collected, and pRb levels were measured
by western blots. Surprisingly, despite lacking the conserved LXCXE
motif, CPV-2 E7 was still able to degrade pRb in HFKs, MDCKs
and CPEKs (Figure 1B, C and D). To test whether the lower level of
pRb was due to a change at the transcriptional level, RT-PCR was
performed to measure the level of pRb mRNA. There was no
significant difference between the amount of pRb mRNA in control
cells and cells with CPV-2 E7 (Figure 1E). In addition, treatment of
the E7 expressing cells with the proteasome inhibitor, MG132,
restored the level of pRb (Figure 1F). These data suggest that the
reduction of pRb by CPV-2 E7 occurs at the protein level rather than
mRNA level, and that degradation is most likely responsible.
The LXSXE motif is not required for binding of pRb by
CPV-2 E7
The degradation of pRb by HPV16 E7 requires high affinity
binding [19]. Since CPV-2 E7 lacks the conserved pRb binding
Figure 1. Despite the lack of a conserved LXCXE motif, CPV-2 E7 still degrades pRb. (A) Alignment of CPV-2 E7, CPV-1E7 and HPV16 E7
protein sequences. The underlined sequence is the conserved LXCXE domain. (B-D) Human foreskin keratinocytes (HFKs), canine MDCK cells or canine
keratinocytes (CPEKs) were infected with control retrovirus or retrovirus encoding for CPV-2 E6 (2E6) or E7 (2E7). Cell lysates were prepared from
indicated cells. Proteins were separated on a 4 to 20% gradient gel and then analyzed by Western blotting using anti-pRb antibody. (E) RNA was
isolated from indicated cells, and RT-PCR was used to measure the level of RNA transcripts. (F) Cell lysates were prepared from cells treated with
control DMSO or 40 um of MG132 for 4 hours. The level of pRb was measured by western blot. In this figure and all following figures, the described
experiments were repeated at least three times, with representative results shown.
doi:10.1371/journal.ppat.1001089.g001
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binding of pRb by CPV-2 E7. It could be either that the LXSXE
motif has the same binding properties as LXCXE, or that CPV-2
E7 has an alternative dominant binding site. We generated E7
mutants (Figure 2A) with mutations within the LXSXE domain to
investigate whether the LXSXE motif exhibits similar binding to
pRb as LXCXE. The GST E7 wild type and mutant fusion
proteins were purified from bacteria (Figure 2B), and tested for
their binding to pRb. As demonstrated in Figure 2C, wild type
CPV-2 E7 binds well to pRb. Substitution of serine26 to cysteine
in CPV-2 E7 significantly increased the interaction between E7
and pRb. This is in agreement with mutagenesis studies showing
that mutation of HPV16 E7 cysteine24 to serine substantially
decreased the binding activity [13,33]. In the studies of HPV16
E7, the substitution of cysteine in LXCXE for glycine abolished
the binding between E7 and pRb [14,33,34,35]. However, for
CPV-2 E7, the pRb binding activity of the glycine mutant protein
was still retained (Figure 2C). More importantly, the deletion of
the entire LXSXE motif did not significantly affect the ability of
CPV-2 E7 to bind pRb. This is very surprising since the deletion of
the LXCXE motif in HPV 16 E7 totally abolished pRb binding
[14,33,34,35]. Thus, while the CPV-2 LXSXE motif exhibits
lower pRb binding than the conserved LXCXE motif, it is clear
that there is an alternative pRb binding site in the CPV-2 E7
protein.
In vitro, the CPV-2 E7 carboxyl-terminal domain mediates
pRb binding
In order to locate potential alternative pRb binding sites in
CPV-2 E7, several CPV-2 E7 truncation mutants were generated
(Figure 3A). CPV-2 E7 protein was divided into CR1 (amino acids
1 to 15), CR2 (amino acids 16 to 38) and the C terminal domains
(amino acids 39 to 98). The GST E7 wild type and mutant fusion
proteins were purified from bacteria (Figure 3B). A binding assay
with GSTE7 mutants and pRb was performed. In agreement with
earlier studies [4,14,36], HPV16 E7CR1CR2 bound pRb much
more efficiently than the HPV16 E7 carboxyl-terminus domain
(Figure 3C), with 6 times more pRb being bound by the combined
CR domains. In contrast, the carboxyl-terminus of CPV-2 E7 has
much higher binding than the CR1 and CR2 domains, on the
average 7 times higher. Importantly, similar binding affinities were
also observed between the canine pRb and CPV-2 E7 (Figure 3D),
indicating that these unique binding interactions were not due to
differences in the species of Rb used for analysis. Thus, CPV-2 E7
uses its carboxyl-terminus instead of the CR1 and CR2 domains to
associate with pRb.
Figure 2. The canine E7 LXSXE motif is not required for pRb binding. (A) Schematic representation of CPV-2 E7 proteins with mutations. (B)
Expression of bacterially expressed GST E7 fusion proteins were confirmed by SDS-PAGE and Coomassie blue staining. (C) GST pull-down experiments
were used to analyze the binding of GST E7 constructs to pRb. Complexes were resolved on 4–20% gradient gels and then analyzed by Western
blotting using anti-pRb antibody or anti-GST antibody. The pRb and GSTE7 proteins were quantified by densitometry. The relative binding activities
were normalized to GSTE7 protein and the wild type CPV-2 E7 GST fusion protein was set to 100%.
doi:10.1371/journal.ppat.1001089.g002
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pRb binding in vivo
To verify that the above in vitro binding studies were relevant to
in vivo conditions, U2OS cells transduced by HA-tagged CPV-2 E7
constructs were used to study the in vivo association of CPV-2 E7
protein and pRb. Co-precipitation experiments were performed
with the anti-pRb antibody (Figure 4). In contrast to results with
HPV 16 E7, the CPV-2 E7 mutant deleted of the LXCXE-like
motif bound pRb as well as the wild-type E7 did. Furthermore, the
carboxy-terminal domain of CPV-2 alone bound to pRb very well.
Thus, both in vitro and in vivo studies indicate that the E7 carboxyl-
terminus mediates pRb binding. The level of canine E7 CR1CR2
construct was not detectable in the cell since it appears to be
unstable. The doublet band noted for both wild-type E7 and the
LXCXE deletion E7 proteins is most likely due to alkylation by
protease inhibitors during the IP procedure. In previous studies, we
also observed two distinct forms of HPV-16 E7 and showed that
they were generated in vitro by the alkylating reagents, TPCK and
TLCK [37]. These reagents are used as a component of a protease-
inhibitor cocktail during IP studies to prevent protein degradation.
We identified cysteine27 near the amino terminus of HPV-16E7 as
the alkylation target. In our current study, we did not observe this
modification of HPV-16 E7, apparently due to interference by the
amino-terminal epitope tag. In the published study where we
observed alkylated HPV-16 E7, we had used an E7 protein tagged
at its C-terminus. We presume that the CPV-2 E7 protein is being
modified in a similar fashion, although different sites might be
altered than in HPV-16 E7.
Unlike HPV-16 E7, the CPV-2 E7 carboxyl-terminus
domain is critical for destabilization of pRb
Since the mechanism used by CPV-2 E7 to bind pRb is
different from that used by HPV E7, it was also possible that the
two E7 proteins used alternative methods to degrade pRb. To test
this possibility, a series of E7 deletion and single amino acid
substitution mutants were generated. Keratinocytes were trans-
duced with retrovirus encoding either wild type E7 or E7
mutants. Cell lysates were collected, and the level of pRb was
measured with immunoblots. Surprisingly, the LXSXE-deletion
mutant (which retains pRb binding) lost the ability to degrade
pRb (Figure 5A). In addition, when the serine at 26 was changed
to cysteine (which increases pRb binding), the degradation of
pRb was not enhanced (Figure 5A). Thus, although the primary
pRb binding of CPV-2 resides in the carboxyl-terminus, we
observed that the amino-terminal LXSXE sequence is necessary
for the degradation of pRb. Neither the E7 amino- nor carboxyl-
Figure 3. The carboxyl-terminus of canine E7 protein mediates pRb binding in vitro. (A) Schematic representation of CPV-2 E7 proteins
with mutations. CPV-2 E7 protein was divided into CR1 (amino acids 1 to 15), CR2 (amino acids 16 to 38) and C terminal domains (amino acids 39 to
98). (B) Expression of bacterially expressed GST tagged E7 truncated mutants were confirmed by SDS-PAGE and Coomassie blue staining. GST pull-
down experiments were used to analyze the binding of GST E7 constructs to human pRb (C) and canine pRb (D). Complexes were resolved on 4–20%
gradient gels and then analyzed by Western blotting using anti-pRb antibody or anti-GST antibody. The bands of pRb and GSTE7 proteins were
quantified by densitometry. The relative binding activities were calculated using pRb bound by wild type CPV-2 E7 GST fusion protein as 100%, and
normalized with GSTE7 bands.
doi:10.1371/journal.ppat.1001089.g003
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This is in contrast to studies performed on high risk HPV E7
(reviewed by Munger [38]) showing that the sequences important
for binding and degradation of pRb localized to CR1 and CR2.
Another difference between HPV16 E7 and CPV-2 E7 is
highlighted by previous studies showing that HPV16 E7
associates with the cullin 2 ubiquitin ligase complex and that
this association contributes to degradation of pRb [4,14,36]. This
does not appear to be true for CPV-2 E7 protein. Co-
immunoprecipitation assays failed to detect any association of
Cullin2 with CPV-2 E7 (Figure 5C).
A gamma HPV E7 protein also binds pRb via its carboxyl-
terminus
Our current results demonstrate that at least one animal
papillomavirus uses a different mechanism to bind and degrade
pRb. To investigate whether some HPVs might use a similar
alternative binding mechanism, we screened a papillomavirus
phylogentic tree based upon the E7 protein sequence (Figure 6A).
E7 proteins from 33 HPVs and 15 animal papillomaviruses were
selected according to their genus [39] and aligned using Clustal
W [40] with MEGA version 4.0 [32]. Based on the alignment, a
phyllogenetic tree was assembled by using the minimum
evolution method with MEGA version 4.0 [32]. CPV-2 E7 was
most closely related to the genus gamma-papillomaviruses (HPV-
4, 48, 50, 60, 65, 88, 95 and 116) and only distantly related to the
genus lambda-papillomaviruses (CPV-1 and Felis domesticus
papillomavirus). Interestingly, the alignment of E7 proteins
revealed that all the gamma HPVs lack the LXCXE motif
(Figure 6B) and, indeed, nearly all these gamma-HPVs contain
the same LXSXE sequence found in CPV-2. One of the gamma-
HPVs, HPV60, contains alanine rather than serine in the
LXSXE sequence. To test the binding of a representative
gamma-HPV E7 to pRb, HPV-4 E7 was synthesized and cloned
into an expression vector. HPV-4 E7 protein was divided into
CR1 (amino acids 1 to 15), CR2 (amino acids 16 to 38) and
carboxyl-terminal domains (amino acids 39 to 100) (Figure 6C).
Wild type HPV-4 E7 and truncation mutants were expressed as
GST fusion proteins (Figure 6D) and tested for their abilities to
bind pRb. Similar to CPV-2 E7, the HPV-4 E7 protein contained
an LXSXE motif and bound pRb (Figure 6E). More interestingly,
as shown in Figure 6E, the carboxyl- terminus of HPV-4 E7
bound pRb more efficiently than the CR1CR2 domains. It
appears, therefore, that the gamma-type HPVs and CPV-2 share
a mechanism by which their E7 proteins interact with pRb via
the carboxyl-terminal domain.
HPV-4 E7 is able to degrade pRb
Due to the similar ability of the CPV-2 and HPV-4 E7 proteins
to bind pRb, we also evaluated whether HPV-4 E7 could degrade
pRb. In HFKs, HPV-4 E7 reduced the level of pRb in
transduced cells, although somewhat less than observed with
CPV-2 or HPV16 E7 (Figure 7A). To test whether the lower level
of pRb protein might be due to altered gene transcription, we
measured pRb mRNA levels by RT-PCR. There was no
significant difference in the amount of pRb mRNA in the control
cells compared to cells expressing CPV-2 E7 (Figure 7B),
indicating that the pRb protein changes were post-translational.
More importantly, treatment of the E7 expressing cells with
proteasome inhibitor, MG132, restored the level of pRb protein
Figure 4. The carboxyl-terminus of canine E7 protein also mediates in vivo binding to pRb. U2OS cells were co-transfected with a series
of HA-tagged E7 mutants and Rb expression plasmids. Immuno-precipitation was performed with anti-pRb antibody and the pull-down complexes
were resolved on a 4 to 20% gradient gel and then analyzed by Western blotting using either anti-pRb antibody or anti-HA antibody. The total
relative level of E7 proteins expressed in the transfected cells is shown in the lower panel (diluted 1:10).
doi:10.1371/journal.ppat.1001089.g004
New Mechanism for E7 Association with pRb
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the reduction of pRb by HPV-4 E7 is most likely the result of
protein degradation.
Discussion
Small DNA tumor viruses, such as HPV, Adenovirus, and
Polyomavirus, produce viral oncoproteins that can interact with
pRb and alter its function.TargetingpRbappears important for the
ability of these viruses to regulate E2F and cell DNA replication and
to complete the virus life cycle.Alltheseoncoproteins, E7,E1A, and
LT, use a conserved CR2 domain and LXCXE motif to bind pRb
[41]. However, for CPV-2 E7, the LXCXE-like motif is not
necessary for associationwith ordegradation of pRb. It appears that
CfPV has evolved an alternative mechanism to bind pRb by using
the E7 carboxyl-terminal domain.
Although the HPV E7 carboxyl-terminus has been proposed to
have an independent, low affinity pRb binding site [14,36],
HPV16 E7 mutants with a deletion of the LXCXE motif in CR2
fail to associate with pRb family members as determined by
Western blotting and extensive proteomic analyses of associated
cellular protein complexes [4]. In contrast, the carboxyl-terminus
of CPV-2 E7 exhibits greater pRb binding than the CR1 and CR2
domains. Even more interesting is the finding that the CPV-2 E7
mutant deleted of the LXSXE domain still can bind to pRb with
high efficiency. Furthermore, the carboxyl-terminus of CPV-2 E7
alone can bind pRb in vitro and in vivo. The carboxyl-terminus of
HPV E7 has been proposed to be important for releasing E2F
from pRb [20,21]. It will be interesting to map the association site
on pRb, and to determine whether the binding induces the release
of E2F from pRb.
During preparation of this manuscript, three new canine
papillomaviruses were identified [42]. One of the viruses, CPV7,
shares high sequence homology with CPV-2 and its predicted E7
ORF encodes a protein with the LXSXE motif. Overall, however,
5 of the 7 identified canine papillomaviruses contain the LXCXE
motif in their E7 protein. CPV-1 E7, which has LXCXE motif,
degrades pRb in cells as anticipated (data not shown).
Figure 5. Although not the primary binding site, the canine E7 amino-terminal domain of CPV-2 E7 is important for destabilization
of pRb. Keratinocytes were infected by retrovirus encoding wild type E7, E7 mutants with mutation on the LXSXE motif (A), or the domain truncation
mutants (B). Cell lysates were prepared from indicated cells. Proteins were separated on a 4 to 20% gradient gel and then analyzed by Western
blotting using anti-pRb antibody. (C) Cell lysates were prepared from Hela cells transfected with pJs55, pJS55-HA.HPV16 E7 or pJS55-HA.CPV-2 E7.
Immuno-precipitation assay was performed with anti-HA antibody. The pulled down complexes were resolved on a 4 to 20% gradient gel and then
analyzed by Western blotting using either anti-Cullin2 antibody or anti-HA antibody.
doi:10.1371/journal.ppat.1001089.g005
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PLoS Pathogens | www.plospathogens.org 7 September 2010 | Volume 6 | Issue 9 | e1001089Figure 6. Similarities of the CPV-2 and gamma HPV E7 proteins. (A) Phylogenetic analysis of papillomavirus E7 gene sequences. The E7 gene
of CPV-2 was compared with 33 HPV and 15 animal PV DNA sequences in order to establish its closest relatives. The analyzed papillomavirus
genomes included were FcPV (K02019), bovine BPV1 (NC_001522), BPV2 (NC_001521), BPV3 (NC_004197)BPV4 (X05817), canine oral CPV-1
(NC_001619), Canine papillomavirus type 2 CPV-2 (AY722648), cotton rabbit CRPV (NC_001541), deer DPV (NC_001523), Equus caballus EcPV1
(AF498323), European elk EEPV (NC_001524), Felis domesticus FdPV1 (AF480454), Hamster oral HaOPV (E15110), HPV1 (NC_001356), HPV3
(NC_001588), HPV-4 (NC_001457), HPV5 (NC_001531), HPV6b (NC_000904), HPV9 (NC_001596), HPV10 (X74465), HPV16 (NC_001526), HPV18
(NC_001357), HPV26 (X74472), HPV29 (NC_001685), HPV32 (X74475), HPV34 (X74476), HPV-41 (X56147), HPV-42 (M73236), HPV-48 (NC_001690), HPV-
49 (NC_001591), HPV50 (NC_001691), HPV53 (NC_001593), HPV54 (U37488), HPV60 (NC_001693), HPV61 (U31793), HPV63 (X70828), HPV90
(AY057438), HPV92 (AF531420), HPV94 (AJ620211), HPV96 (AY382779), Mastomys natalensis MnPV (NC_001605), Ovine OvPV1 (NC_001789), OvPV2
(NC_001790), Psittacus erithacus PePV (AF502599), Phocoena spinipinnis PsPV1 (NC_003348) and rabbit oral ROPV (NC_002232). (B) E7 proteins from
CPV-2 and Gamma HPVs papillomaviruses were selected, and aligned using Clustal W with MEGA version 4.0. The conserved LXSXE domain is
underlined. (C) Schematic representation of HPV-4 E7 proteins with mutations. HPV-4 E7 protein was divided into CR1 (amino acids 1 to 15), CR2
(amino acids 16 to 38) and C terminus domains (amino acids 39 to 100). (D) Expression and purification of bacterial expressed GST tagged E7
truncated mutants were confirmed by SDS-PAGE and Coomassie blue staining. (E) GST pull down experiments were used to analyze the binding of
GST E7 constructs to pRb. Complexes were resolved on a 4 to 20% gradient gel and then analyzed by Western blotting using anti-pRb antibody or
anti-GST antibody. Densitometry was used to measure the relative binding activities and normalized with GSTE7 bands.
doi:10.1371/journal.ppat.1001089.g006
New Mechanism for E7 Association with pRb
PLoS Pathogens | www.plospathogens.org 8 September 2010 | Volume 6 | Issue 9 | e1001089As shown in this study, the LXSXE motif is not limited to
canine papillomaviruses; the gamma genus of HPVs also have the
same motif. This genus consists of eight HPVs, 7 of which contain
the E7 LXSXE motif. Interestingly, the gamma HPVs have
several other similarities to CPV-2. First, they induce cutaneous
rather than mucosal lesions. Second, they most likely persist in the
population as subclinical infections and induce visually detectable
tumors only under conditions of immunosuppression. Third, their
tumor cells are characterized by histologically-distinguishable
intracytoplasmic inclusion bodies [39]. The canine model may
provide a new approach for studying the biology of this unique
category of papillomaviruses and their stringent regulation by the
host immune response.
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